Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Study of Bone Marrow Collagen Fibrosis After Romiplostim in ITP
2008-004347-10Phase 4Completed
- Sponsor
- Amgen
- Start
- May 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Amgen. Primary endpoints: Incidence of bone marrow collagen fibrosis at Years 1–3 and Presence of collagen fibrosis 12 weeks after romiplostim discontinuation. Started May 2009; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2008-004347-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004347-10.